Albert Y Lin

Summary

Affiliation: Santa Clara Valley Medical Center
Country: USA

Publications

  1. pmc Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, United States of America
    PLoS ONE 6:e16636. 2011
  2. doi request reprint Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 10:63-9. 2011
  3. doi request reprint Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis
    An Ting T Lu
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 8:207-14. 2009
  4. doi request reprint Impact of initial surgical margins and residual cancer upon re-excision on outcome of patients with localized breast cancer
    Natalia B Kouzminova
    Department of Hematology Oncology, Santa Clara Valley Medical Center, Santa Clara, CA, USA
    Am J Surg 198:771-80. 2009
  5. doi request reprint Characteristics of colorectal cancer survival in an urban county hospital
    Vincent K Lam
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    J Gastrointest Cancer 44:68-72. 2013
  6. doi request reprint Phase II study of imatinib in unresectable hepatocellular carcinoma
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, 751 S Bascom Avenue, San Jose, CA 95128, USA
    Am J Clin Oncol 31:84-8. 2008

Collaborators

Detail Information

Publications6

  1. pmc Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, United States of America
    PLoS ONE 6:e16636. 2011
    ..We sought to identify genes of clinical significance to predict survival and the risk for colorectal liver metastasis (CLM), the most common site of metastasis from colorectal cancer (CRC)...
  2. doi request reprint Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 10:63-9. 2011
    ..Emerging data suggest that somatic KRAS mutation in advanced colorectal cancer is a strong predictor of non-response to anti-epidermal growth factor receptor antibody (anti-EGFR) therapy...
  3. doi request reprint Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis
    An Ting T Lu
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 8:207-14. 2009
    ..We performed a systematic review and meta-analysis of gene expression profiles (GEPs) to assess their utility for risk stratification and prediction of poor outcomes in stage II CRC...
  4. doi request reprint Impact of initial surgical margins and residual cancer upon re-excision on outcome of patients with localized breast cancer
    Natalia B Kouzminova
    Department of Hematology Oncology, Santa Clara Valley Medical Center, Santa Clara, CA, USA
    Am J Surg 198:771-80. 2009
    ..The aim of this study was to assess the impact of initial margins and residual carcinoma found on second surgery on the outcomes of breast cancer patients...
  5. doi request reprint Characteristics of colorectal cancer survival in an urban county hospital
    Vincent K Lam
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    J Gastrointest Cancer 44:68-72. 2013
    ..We examined CRC outcomes in an urban underserved population with sociodemographic factors distinctly different than those previously studied...
  6. doi request reprint Phase II study of imatinib in unresectable hepatocellular carcinoma
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, 751 S Bascom Avenue, San Jose, CA 95128, USA
    Am J Clin Oncol 31:84-8. 2008
    ..Imatinib, a potent inhibitor of BCR-ABL and c-kit, also inhibits the platelet-derived growth factor receptor tyrosine kinase. The trial was designed to assess the efficacy and safety of imatinib in patients with unresectable HCC...